Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 4/20 | 0.45 |
| ▸ | TMPRSS6 | Q8IU80 | 4/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperidine SCHEMBL23882947 | 0.92 | ITGB1 (0.49) | ITGB1ITGA4MEN1KMT2AF2 | |
| SCHEMBL8823969 | 0.83 | CA2 (0.56) | F2TMPRSS6F10CA2CA1 | |
| SCHEMBL7361857 | 0.81 | F2 (0.58) | ITGB1ITGA4F2TMPRSS6F10 | |
| SCHEMBL9664076 | 0.76 | PLG (0.56) | F10PLAUPLG | |
| SCHEMBL6572028 | 0.72 | SLC1A3 (0.57) | MEN1KMT2AF2CA2CA1 | |
| Hydrochloric Acid SCHEMBL9710413 | 0.71 | F2 (0.53) | F2TMPRSS6F10CA2ITGB3 | |
| SCHEMBL5634327 | 0.70 | LMNA (0.54) | ITGB1F2CA2CA1ITGB3 | |
| SCHEMBL5634324 | 0.70 | LMNA (0.54) | ITGB1F2CA2CA1ITGB3 | |
| SCHEMBL27146770 | 0.70 | MMP2 (0.59) | ITGB1ITGA4MEN1KMT2AF10 | |
| SCHEMBL27146771 | 0.70 | MMP2 (0.59) | ITGB1ITGA4MEN1KMT2AF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021096897-A1 | ANTIMICROBIAL AND ANTIVIRAL, BIOLOGICALLY ACTIVE POLYMER COMPOSITES EFFECTIVE AGAINST SARS-COV-2 AND OTHER VIRAL, BACTERIAL AND FUNGAL TARGETS, AND RELATED METHODS, MATERIALS, COATINGS AND DEVICES | IASIS MOLECULAR SCIENCES, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20170304815-A1 | Antimicrobial And Biological Active Polymer Composites And Related Methods, Materials and Devices | VACHON DAVID JOHN (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3190881-A1 | ANTIMICROBIAL AND BIOLOGICALLY ACTIVE POLYMER COMPOSITES AND RELATED METHODS, MATERIALS AND DEVICES | Iasis Molecular Sciences (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040529-A1 | ANTIMICROBIAL AND BIOLOGICALLY ACTIVE POLYMER COMPOSITES AND RELATED METHODS, MATERIALS AND DEVICES | IASIS MOLECULAR SCIENCES (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2015071841-A1 | COMPLEXES OF DABIGATRAN AND ITS DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Druggability Technologies Holdings Limited (IE) | 2015-05-21 | — | — | WO | disclosed |
| US-20100292183-A1 | TETRACYCLINE AND USES THEREOF | PLAXGEN, INC. | 2010-11-18 | — | — | US | disclosed |
| WO-2001079195-A2 | PYRIDINE AND PYRAZINE DERIVATIVES AS THROMBIN INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| US-5250720-A | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
| US-5242904-A | Anticoagulant, antiinflammatory | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-09-07 | — | — | US | disclosed |
| US-5187157-A | Anticoagulant, antiinflammatory agents | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292183-A1 | TETRACYCLINE AND USES THEREOF | TET1, TET3, TNNT2 | ITGB1 1842/4885ITGA4 1151/4885MEN1 3295/4885 |
| US-20170304815-A1 | Antimicrobial And Biological Active Polymer Composites And Related Methods, Materials and Devices | PHOSPHO1, PGLS, PUF60 | ITGB1 394/4885ITGA4 381/4885MEN1 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.